Institute of Medicine Report Criticizes Quality of Cancer Care

Publication
Article
OncologyONCOLOGY Vol 13 No 6
Volume 13
Issue 6

There are serious shortcomings in the quality of care for manyAmericans with cancer, according to a report just released by the Institute of Medicine National Cancer Policy Board. Deficits in care identified in the report include underuse of screening

There are serious shortcomings in the quality of care for manyAmericans with cancer, according to a report just released by the Institute of Medicine National Cancer Policy Board. Deficits in care identified in the report include underuse of screening tests, lack of adherence to standards for diagnosis, inadequate patient counseling regarding treatment options, and underuse of radiation therapy and adjuvant chemotherapy after surgery. Joseph Simone, MD, medical director, Huntsman Cancer Foundation and Institute, which is affiliated with the University of Utah, headed the board that prepared the report.

The board recommended that patients who need complicated cancer surgery or chemotherapy be treated at facilities that perform a high volume of these procedures. Such procedures include removal of all or part of the esophagus, surgery for pancreatic cancer, removal of pelvic organs, and complex chemotherapy treatments. Survival rates immediately following these procedures are two to three times higher when done in more experienced facilities, according to several studies reviewed in this report.

Improving cancer care in all settings will require new efforts to track the quality of individual health plans, and to hold providers and insurers accountable. The prepublication version of the report can be downloaded from www.nap.edu.

Recent Videos
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
4 experts in this video
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Related Content